The spending has enabled the 81-year-old business to establish fully integrated capabilities spanning the entire drug lifecycle and world-leading expertise in HDAC6 biology. CKD is developing non ...

Augustine’s approach focuses on inhibiting the cytosolic histone deacetylase 6 (HDAC6) enzyme, which plays a key role in neurodegeneration and aging-related cellular processes. The company’s ...

The Leven, Belgium-based biotech has built its business around a series of inhibitors of the HDAC6 enzyme, which is implicated in various neuromuscular, neurodegenerative, and cardio-metabolic ...

Augustine Therapeutics builds its Management Team with Virginie Cartage joining as CFO and Dr. Andy Hu as CBO </s ...

With support from the NC3Rs we are refining the widely used SOD1G93A model of motor neuron disease. Preclinical testing of HDAC6 inhibition in a zebrafish model of CMT2A (Hereditary Neuropathy ...

Having worked as an advisor, I have had a first-hand opportunity to appreciate the cutting-edge science behind Augustine's next-generation HDAC6 inhibitors (HDAC6i) and look forward to maximizing ...